|

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

RECRUITINGN/ASponsored by Centre Jean Perrin
Actively Recruiting
PhaseN/A
SponsorCentre Jean Perrin
Started2025-10-13
Est. completion2029-04
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07178847

Summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Selection Criteria:

* Patient included in NeckTAR study
* Written informed consent signed for NeckTAR-IN study
* Affiliation to the French social security system

Conditions2

CancerLocally Advanced Head and Neck Carcinoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.